Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.
BACKGROUND
We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.


METHODS
We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.


RESULTS
The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.


CONCLUSIONS
Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Byung Woog
BW
Kang
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Sang Kyun
SK
Sohn
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Joon Ho
JH
Moon
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Yee Soo
YS
Chae
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Jong Gwang
JG
Kim
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
Soo Jung
SJ
Lee
Department of Hematology/Oncology, Internal Medicine, Samsung Medical Center, Seoul, Korea.
Won Seog
WS
Kim
Department of Hematology/Oncology, Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Je-Jung
JJ
Lee
Department of Hematology/Oncology, Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
Se Ryeon
SR
Lee
Department of Hematology/Oncology, Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Keon Uk
KU
Park
Department of Hematology/Oncology, Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Ho Sup
HS
Lee
Department of Hematology/Oncology, Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
Won Sik
WS
Lee
Department of Hematology/Oncology, Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea.
Jong-Ho
JH
Won
Department of Hematology/Oncology, Internal Medicine, Wonkwang University Hospital, Iksan, Korea.
Moo-Rim
MR
Park
Department of Hematology/Oncology, Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
Jae-Yong
JY
Kwak
Department of Hematology/Oncology, Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Min Kyoung
MK
Kim
Department of Hematology/Oncology, Internal Medicine, Hallym University Scared Heart Hospital, Anyang, Korea.
Hyo Jung
HJ
Kim
Department of Hematology/Oncology, Internal Medicine, Dong-A University Hospital, Busan, Korea.
Sung Yong
SY
Oh
Department of Hematology/Oncology, Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.
Hye Jin
HJ
Kang
Department of Hematology/Oncology, Internal Medicine, Asan Medical Center, Seoul, Korea.
Cheolwon
C
Suh
Chemotherapy; Epidemiology; Mantle cell lymphoma; Rituximab; Survival; Trend